---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116762"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:16:11.211022+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea

## Summary
- FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.
- Net product revenues $14.6M, down 4% YoY; Qbrexza sales up 29% to $7.6M.
- Net loss $2.4M ($0.12/sh) vs net income $16.8M ($0.91/sh) in Q3 2023 (included $19M license payment).
- Adjusted EBITDA $0.3M ($0.01/sh) vs $20.8M ($1.13/sh) in Q3 2023.
- Gross margin improved to 63.9% from 57.9% due to lower inventory charges and royalties.

## SEC filing metadata
- accession: 0001104659-24-116762
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/0001104659-24-116762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465924116762/tm2428053d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116762
- JSON: https://secwatch.observer/filing/0001104659-24-116762.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116762.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.